Contemporary role of advanced imaging for bladder cancer staging.

[1]  P. Choyke,et al.  Advances in medical imaging for the diagnosis and management of common genitourinary cancers. , 2017, Urologic oncology.

[2]  P. Pierorazio,et al.  Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer. , 2017, Urology.

[3]  S. Daneshmand,et al.  Preoperative Imaging for Clinical Staging Prior to Radical Cystectomy , 2016, Current Urology Reports.

[4]  Xiangyu Yang,et al.  Prediction of chemotherapeutic response in bladder cancer using K‐means clustering of dynamic contrast‐enhanced (DCE)‐MRI pharmacokinetic parameters , 2015, Journal of magnetic resonance imaging : JMRI.

[5]  Daniele Marin,et al.  Emerging applications for ferumoxytol as a contrast agent in MRI , 2015, Journal of magnetic resonance imaging : JMRI.

[6]  M. McInnes,et al.  Multiparametric MRI of solid renal masses: pearls and pitfalls. , 2015, Clinical radiology.

[7]  Choung-Soo Kim,et al.  FDG PET–CT for Lymph Node Staging of Bladder Cancer: A Prospective Study of Patients with Extended Pelvic Lymphadenectomy , 2015, Annals of Surgical Oncology.

[8]  U. Nagele,et al.  Technical solutions to improve the management of non‐muscle‐invasive transitional cell carcinoma: summary of a European Association of Urology Section for Uro‐Technology (ESUT) and Section for Uro‐Oncology (ESOU) expert meeting and current and future perspectives , 2015, BJU international.

[9]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[10]  C. West,et al.  Dynamic contrast-enhanced magnetic resonance imaging biomarkers in head and neck cancer: potential to guide treatment? A systematic review. , 2014, Oral oncology.

[11]  J. Dobruch,et al.  Clinical value of transurethral second resection of bladder tumor: systematic review. , 2014, Urology.

[12]  J. Witjes,et al.  Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA , 2014, Nature Reviews Urology.

[13]  P. Dasgupta,et al.  Role of fluorodeoxyglucose positron emission tomography (FDG PET)‐computed tomography (CT) in the staging of bladder cancer , 2014, BJU international.

[14]  R. Coleman,et al.  Impact of 18F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry , 2014, The Journal of Nuclear Medicine.

[15]  Jurgen J Fütterer,et al.  Multiparametric MRI of the bladder: ready for clinical routine? , 2014, AJR. American journal of roentgenology.

[16]  A. Jemal,et al.  Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. , 2014, International journal of radiation oncology, biology, physics.

[17]  Baris Turkbey,et al.  Role of Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer , 2014, Current Urology Reports.

[18]  Kazutaka Saito,et al.  Apparent diffusion coefficient value reflects invasive and proliferative potential of bladder cancer , 2014, Journal of magnetic resonance imaging : JMRI.

[19]  Maria Triantafyllou,et al.  Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. , 2013, European urology.

[20]  J. Witjes,et al.  Ferumoxtran-10 ultrasmall superparamagnetic iron oxide-enhanced diffusion-weighted imaging magnetic resonance imaging for detection of metastases in normal-sized lymph nodes in patients with bladder and prostate cancer: do we enter the era after extended pelvic lymph node dissection? , 2013, European urology.

[21]  P. Choyke,et al.  Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. , 2013, The Journal of urology.

[22]  D. Chakraborty,et al.  Comparison of 18F Fluoride PET/CT and 99mTc-MDP Bone Scan in the Detection of Skeletal Metastases in Urinary Bladder Carcinoma , 2013, Clinical nuclear medicine.

[23]  Timothy C. Chang,et al.  Interobserver agreement of confocal laser endomicroscopy for bladder cancer. , 2013, Journal of endourology.

[24]  B. V. van Rhijn,et al.  FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer. , 2013, The Journal of urology.

[25]  Yair Lotan,et al.  ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. , 2013, European urology.

[26]  S. Daneshmand,et al.  Preoperative staging of invasive bladder cancer with dynamic gadolinium-enhanced magnetic resonance imaging: results from a prospective study. , 2012, Urology.

[27]  H. Hricak,et al.  Prospective evaluation of MRI, ¹¹C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. , 2012, European journal of radiology.

[28]  Changjian Zheng,et al.  Narrow band imaging diagnosis of bladder cancer: systematic review and meta‐analysis , 2012, BJU international.

[29]  Rajesh Kumar,et al.  Selective sampling using confocal Raman spectroscopy provides enhanced specificity for urinary bladder cancer diagnosis , 2012, Analytical and Bioanalytical Chemistry.

[30]  M. Schwaiger,et al.  Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. , 2012, European urology.

[31]  O. Gofrit,et al.  11C-Acetate PET/CT in Bladder Urothelial Carcinoma: Intraindividual Comparison With 11C-Choline , 2012, Clinical nuclear medicine.

[32]  M. Gallucci,et al.  Diffusion‐weighted magnetic resonance imaging in patients selected for radical cystectomy: detection rate of pelvic lymph node metastases , 2012, BJU international.

[33]  H. Thoeny,et al.  Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. , 2012, European urology.

[34]  A. Graser,et al.  Staging of muscle-invasive bladder cancer: can computerized tomography help us to decide on local treatment? , 2012, World Journal of Urology.

[35]  S. Larson,et al.  Initial Results with 11C-Acetate Positron Emission Tomography/Computed Tomography (PET/CT) in the Staging of Urinary Bladder Cancer , 2012, Molecular Imaging and Biology.

[36]  H. Herr,et al.  Reduced bladder tumour recurrence rate associated with narrow‐band imaging surveillance cystoscopy , 2011, BJU international.

[37]  M. Gee,et al.  Appearance of primary lymphoid malignancies on lymphotropic nanoparticle-enhanced magnetic resonance imaging using ferumoxtran-10. , 2010, Clinical imaging.

[38]  M. Harisinghani,et al.  Detection of lymph nodes in pelvic malignancies with Computed Tomography and Magnetic Resonance Imaging. , 2010, Clinical imaging.

[39]  L. Lacombe,et al.  Evaluation of fluorodeoxyglucose positron‐emission tomography with computed tomography for staging of urothelial carcinoma , 2010, BJU international.

[40]  J. Capala,et al.  ‘Image and treat’: an individualized approach to urological tumors , 2010, Current opinion in oncology.

[41]  A. Maes,et al.  FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. , 2010, European urology.

[42]  S. Anand,et al.  Forced diuresis and dual-phase 18F-fluorodeoxyglucose-PET/CT scan for restaging of urinary bladder cancers , 2010, Indian Journal of Radiology and Imaging.

[43]  A. Karlström,et al.  186Re-maSGS-ZHER2:342, a potential Affibody conjugate for systemic therapy of HER2-expressing tumours , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[44]  Cary Siegel,et al.  Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Kanematsu,et al.  Preoperative T staging of urinary bladder cancer: does diffusion-weighted MRI have supplementary value? , 2009, AJR. American journal of roentgenology.

[46]  Yuta Shibamoto,et al.  Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade. , 2009, Radiology.

[47]  Maria Triantafyllou,et al.  Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. , 2009, European urology.

[48]  Tarek El-Diasty,et al.  Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging , 2009, European Radiology.

[49]  Adilson Prando,et al.  Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade , 2009 .

[50]  S. Baltacı,et al.  Computerized Tomography for Detecting Perivesical Infiltration and Lymph Node Metastasis in Invasive Bladder Carcinoma , 2008, Urologia Internationalis.

[51]  H. Herr,et al.  A comparison of white‐light cystoscopy and narrow‐band imaging cystoscopy to detect bladder tumour recurrences , 2008, BJU international.

[52]  Anke M Hövels,et al.  MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. , 2008, The Lancet. Oncology.

[53]  Soroush Rais-Bahrami,et al.  Optical coherence tomography of cavernous nerves: a step toward real-time intraoperative imaging during nerve-sparing radical prostatectomy. , 2008, Urology.

[54]  A. Goh,et al.  Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. , 2007, Urology.

[55]  E. Glatstein.  Value of 11C-Choline PET and Contrast-Enhanced CT for Staging of Bladder Cancer: Correlation with Histopathologic Findings , 2008 .

[56]  K. Bouchelouche,et al.  Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. , 2008, The Journal of urology.

[57]  H. Grossman,et al.  A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. , 2007, The Journal of urology.

[58]  Unyime Nseyo,et al.  A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. , 2007, The Journal of urology.

[59]  Dalton A Anjos,et al.  18F-FDG PET/CT Delayed Images After Diuretic for Restaging Invasive Bladder Cancer , 2007, Journal of Nuclear Medicine.

[60]  Yair Lotan,et al.  Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. , 2007, European urology.

[61]  Fuminari Tatsugami,et al.  Diffusion-weighted MR imaging for urinary bladder carcinoma: initial results , 2006, European Radiology.

[62]  J. Montie.  Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. , 2005, The Journal of urology.

[63]  D. Bluemke,et al.  Dynamic MRI of bladder cancer: evaluation of staging accuracy. , 2005, AJR. American journal of roentgenology.

[64]  Ernst J. Rummeny,et al.  MR cystography for bladder tumor detection , 2004, European Radiology.

[65]  Jeong Kon Kim,et al.  Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. , 2004, Radiology.

[66]  Eyal Mishani,et al.  Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[67]  S. Donat.  Evaluation and follow-up strategies for superficial bladder cancer. , 2003, Urologic clinics of North America.

[68]  E. Rummeny,et al.  Tumors of the urinary bladder: technique, current use, and perspectives of MR and CT cystography , 2003, Abdominal Imaging.

[69]  Ralph Weissleder,et al.  Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. , 2003, The New England journal of medicine.

[70]  P. Silverman,et al.  Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder , 2003 .

[71]  D. Bluemke,et al.  MR imaging features of transitional cell carcinoma of the urinary bladder. , 2003, AJR. American journal of roentgenology.

[72]  Marc Seltzer,et al.  Positron emission tomography in urologic oncology. , 2002, Cancer control : journal of the Moffitt Cancer Center.

[73]  Marcus Settles,et al.  Reliability of MR imaging-based virtual cystoscopy in the diagnosis of cancer of the urinary bladder. , 2002, AJR. American journal of roentgenology.

[74]  M. Resnick,et al.  Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. , 2000, The Journal of urology.

[75]  H. Herr,et al.  The value of a second transurethral resection in evaluating patients with bladder tumors. , 2000, The Journal of urology.

[76]  M. R. W. Engelbrecht,et al.  MR imaging of the male pelvis , 1999, European Radiology.

[77]  N Karssemeijer,et al.  Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imaging. , 1996, Radiology.

[78]  B. Långström,et al.  Positron Emission Tomography in the Diagnosis and Staging of Urinary Bladder Cancer , 1996, Acta radiologica.